These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35205315)

  • 61. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of hub genes and pathways in cholangiocarcinoma by coexpression analysis.
    Kong J; Shen S; Zhang Z; Wang W
    Cancer Biomark; 2020; 27(4):505-517. PubMed ID: 32116234
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
    Saborowski A; Vogel A; Segatto O
    Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
    Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
    Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy.
    Sato Y; Tanaka S; Kinoshita M; Takemura S; Shinkawa H; Kokudo T; Hasegawa K; Tanaka H; Yoshimoto H; Mori A; Yamamura M; Sasaki M; Harada K; Kubo S
    J Hepatobiliary Pancreat Sci; 2020 Nov; 27(11):860-869. PubMed ID: 32506715
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma.
    Liang J; Liu T; Liao J; Zhang L; Zhou M; Xu W; He Y; Cai G; Jin G; Song J; Li G; Liang H; Ding Z; Zhang B
    J Cell Physiol; 2021 Apr; 236(4):3143-3156. PubMed ID: 32996133
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
    Aukkanimart R; Boonmars T; Juasook A; Sriraj P; Boonjaraspinyo S; Wu Z; Laummuanwai P; Pairojkul C; Khuntikeo N; Rattanasuwan P
    Asian Pac J Cancer Prev; 2015; 16(14):5875-81. PubMed ID: 26320466
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
    Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
    Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SOX4 is associated with poor prognosis in cholangiocarcinoma.
    Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
    Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
    Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular mechanism of cholangiocarcinoma carcinogenesis.
    Maemura K; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
    Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
    Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
    Chong DQ; Zhu AX
    Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
    Chiang NJ; Shan YS; Hung WC; Chen LT
    Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
    Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
    Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
    Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
    BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.